<DOC>
	<DOCNO>NCT01855828</DOCNO>
	<brief_summary>The main goal clinical trial test add pertuzumab ( Perjeta ) , improve anticancer activity combination chemotherapy regimen trastuzumab ( Herceptin ) concomitant paclitaxel , 5-fluorouracil , epirubicin , cyclophosphamide ( T-FEC ) . The study also test safety therapy .</brief_summary>
	<brief_title>Phase 2 Trial Pertuzumab Trastuzumab With Weekly Paclitaxel Chemotherapy HER2 Positive Breast Cancer</brief_title>
	<detailed_description>Subjects receive 6 month T-FEC chemotherapy concomitant trastuzumab pertuzumab surgery . Subsequently , subject undergo surgery remove cancer breast axillary lymph node may survive chemotherapy . It expect majority woman viable cancer leave breast lymph node time chemotherapy complete .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Patients histologically confirm stage IIII , HER2positive invasive breast cancer adjuvant/neoadjuvant chemotherapy indicate base physician judgment follow NCCN practice guideline . HER2 overexpression amplification base local test result define either : ( ) IHC stain 3+ ( uniform , intense membrane stain ) great equal 10 % invasive tumor cell , ( ii ) Fluorescent situ hybridization ( FISH ) result six HER2 gene copy per nucleus , ( iii ) FISH ratio ( HER2 gene signal chromosome 17 signal ) great equal 2.0 . Patients synchronous bilateral breast cancer eligible least one tumor HER2positive . Left Ventricular Ejection Fraction ( LVEF ) great equal 50 % baseline determine either ECHO MUGA , within institution 's normal limit . Women childbearing potential must negative pregnancy test ( serum urine beta HCG ) prior initiation chemotherapy . Both female male breast cancer patient sexually active agree practice contraception participate trial 3 month completion therapy . Adequate bone marrow function indicate follow : ANC great equal 1500/uL Platelets great equal 100,000/uL Hemoglobin great equal 10 g/dL Adequate renal function , indicate creatinine le equal 1.5 time upper limit normal ( ULN ) Adequate liver function , indicate bilirubin less equal 1.5 X ULN AST ALT less equal 2x ULN . Signed informed consent . Patients exclude study base follow criterion : Patients underwent partial excisional biopsy , lumpectomy , segmental mastectomy , modify radical mastectomy sentinel node biopsy , therefore assess pathologic response accurately . Patients high risk develop follow anthracycline , paclitaxel , trastuzumab pertuzumab related toxicity include : History congestive heart failure , myocardial infarction cardiomyopathy , uncontrolled hypertension despite adequate medication Preexisting peripheral neuropathy &gt; grade 3 Prior anthracycline therapy Known hypersensitivity study medication Patients old age 65 due increase risk cardiotoxicity Active infection require systemic antibiotic therapy . Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>